PURPOSE:Exercise training as an add-on to medical therapy has been shown to improve exercise capacity, quality of life, and possibly prognosis in patients with pulmonary hypertension (PH). The purpose of this study was to analyze the impact of exercise training on healthcare costs in PH. METHODS: Estimated healthcare costs have been compared between patients with severe PH under optimized medical therapy only (control group) versus patients who received exercise training as an add-on to medical therapy (training group). Cost-analysis included a cost-estimation model of costs for baseline and follow-up visits and all PH-related healthcare events that occurred within the follow-up period. Time to clinical worsening and survival were assessed by clinical records, phone, and/or control visits. RESULTS: At baseline, the training (n = 58) and control group (n = 48) did not differ in age, gender, WHO-functional class, 6-min walking distance, hemodynamic parameters, or PH-targeted medication. During a follow-up of 24 ± 12 months, the training group had significantly better survival rates at 1 and 3 years and less worsening events (death, lung transplantation, hospitalization due to PH, new PAH-targeted medication) than the control group (15 vs. 25 events, p < 0.05), which also led to lower estimated healthcare costs of 657<euro> within a period of 2 years. CONCLUSIONS: This is the first study to investigate the cost-effectiveness of exercise training in PH. Due to less worsening events within 2 years, healthcare costs were lower in patients performing exercise training as add-on to medical therapy than in patients with medical treatment only. Further prospective, randomized studies are needed to confirm these findings.
RCT Entities:
PURPOSE: Exercise training as an add-on to medical therapy has been shown to improve exercise capacity, quality of life, and possibly prognosis in patients with pulmonary hypertension (PH). The purpose of this study was to analyze the impact of exercise training on healthcare costs in PH. METHODS: Estimated healthcare costs have been compared between patients with severe PH under optimized medical therapy only (control group) versus patients who received exercise training as an add-on to medical therapy (training group). Cost-analysis included a cost-estimation model of costs for baseline and follow-up visits and all PH-related healthcare events that occurred within the follow-up period. Time to clinical worsening and survival were assessed by clinical records, phone, and/or control visits. RESULTS: At baseline, the training (n = 58) and control group (n = 48) did not differ in age, gender, WHO-functional class, 6-min walking distance, hemodynamic parameters, or PH-targeted medication. During a follow-up of 24 ± 12 months, the training group had significantly better survival rates at 1 and 3 years and less worsening events (death, lung transplantation, hospitalization due to PH, new PAH-targeted medication) than the control group (15 vs. 25 events, p < 0.05), which also led to lower estimated healthcare costs of 657<euro> within a period of 2 years. CONCLUSIONS: This is the first study to investigate the cost-effectiveness of exercise training in PH. Due to less worsening events within 2 years, healthcare costs were lower in patients performing exercise training as add-on to medical therapy than in patients with medical treatment only. Further prospective, randomized studies are needed to confirm these findings.
Authors: Ekkehard Grünig; Mona Lichtblau; Nicola Ehlken; Hossein A Ghofrani; Frank Reichenberger; Gerd Staehler; Michael Halank; Christine Fischer; Hans-Jürgen Seyfarth; Hans Klose; Andreas Meyer; Stephan Sorichter; Heinrike Wilkens; Stephan Rosenkranz; Christian Opitz; Hanno Leuchte; Gabriele Karger; Rudolf Speich; Christian Nagel Journal: Eur Respir J Date: 2012-02-09 Impact factor: 16.671
Authors: Ekkehard Grünig; Nicola Ehlken; Ardeschir Ghofrani; Gerd Staehler; F Joachim Meyer; Jana Juenger; Christian F Opitz; Hans Klose; Heinrike Wilkens; Stephan Rosenkranz; Horst Olschewski; Michael Halank Journal: Respiration Date: 2011-02-09 Impact factor: 3.580
Authors: N Nickel; H Golpon; M Greer; L Knudsen; K Olsson; V Westerkamp; T Welte; M M Hoeper Journal: Eur Respir J Date: 2011-09-01 Impact factor: 16.671
Authors: H Wilkens; F Grimminger; M Hoeper; G Stähler; B Ehlken; C Plesnila-Frank; K Berger; A Resch; A Ghofrani Journal: Respir Med Date: 2010-02-09 Impact factor: 3.415
Authors: S Miyamoto; N Nagaya; T Satoh; S Kyotani; F Sakamaki; M Fujita; N Nakanishi; K Miyatake Journal: Am J Respir Crit Care Med Date: 2000-02 Impact factor: 21.405
Authors: Stefan Sohn; Thomas M Helms; Jörg T Pelleter; Axel Müller; Annett I Kröttinger; Oliver Schöffski Journal: Telemed J E Health Date: 2012-02-22 Impact factor: 3.536
Authors: Roland Wensel; Christian F Opitz; Stefan D Anker; Jörg Winkler; Gert Höffken; Franz X Kleber; Rakesh Sharma; Manfred Hummel; Roland Hetzer; Ralf Ewert Journal: Circulation Date: 2002-07-16 Impact factor: 29.690
Authors: Henrik Pettersson; Helene Alexanderson; Janet L Poole; Janos Varga; Malin Regardt; Anne-Marie Russell; Yasser Salam; Kelly Jensen; Jennifer Mansour; Tracy Frech; Carol Feghali-Bostwick; Cecília Varjú; Nancy Baldwin; Matty Heenan; Kim Fligelstone; Monica Holmner; Matthew R Lammi; Mary Beth Scholand; Lee Shapiro; Elizabeth R Volkmann; Lesley Ann Saketkoo Journal: Best Pract Res Clin Rheumatol Date: 2021-07-01 Impact factor: 4.991
Authors: Samantha L Wronski; Margaret Mordin; Kim Kelley; Rebekah H Anguiano; Peter Classi; Eric Shen; Scott Manaker Journal: Lung Date: 2019-11-13 Impact factor: 2.584
Authors: Karen S W Chia; Peter K K Wong; Senen Gonzalez; Eugene Kotlyar; Steven G Faux; Christine T Shiner Journal: Pulm Circ Date: 2020-05-14 Impact factor: 3.017